Pharmacia & Upjohn Camptosar sales are $41.2 mil. in first quarter.

PHARMACIA & UPJOHN CAMPTOSAR SALES ARE $41.2 MIL. IN FIRST QUARTER after less than nine months on the market, the company reported April 29. Camptosar (irinotecan) was launched in August following an accelerated approval for second-line colorectal cancer use ("The Pink Sheet" June 24, 1996, p. 7). The product has generated $99.9 mil. in sales since launch. SmithKline Beecham's campothecin derivative had first quarter sales of $18 mil. ("The Pink Sheet" April 28, p. 18). Camptosar is also marketed by Pharmacia & Upjohn in Argentina, and applications are pending in 11 other countries. The company does not have rights to the drug in Europe or Japan.